Please wait while the formulary information is being retrieved.
HYDROXYPROGESTERONE CAPROATE (HYDROXYPROGESTERONE CAPROATE)
- Risk reduction for recurrent preterm birth
- Abnormal uterine bleeding due to hormonal imbalance
- Adenocarcinoma of corpus uteri
- Amenorrhea
- Endogenous estrogen production test
- Makena Intramuscular Oil
- Hydroxyprogesterone(pf)(pregnancy Preserv) Intramuscular Oil
- Hydroxyprogesterone Caproate Intramuscular Oil
- By Indication
250 mg/mL (1 mL) intramuscular oil
- Inject 1 milliliter (250 mg) by intramuscular route once weekly beginbetween weeks 16 and 20; continue to week 37 of gestation or delivery
250 mg/mL intramuscular oil
- Inject 1 milliliter (250 mg) by intramuscular route once weekly beginbetween weeks 16 and 20; continue to week 37 of gestation or delivery
hydroxyprogesterone (PF)(pregnancy preserving) 250 mg/mL (1 mL) IM oil
- Inject 1 milliliter (250 mg) by intramuscular route once weekly beginbetween weeks 16 and 20; continue to week 37 of gestation or delivery
250 mg/mL intramuscular oil
- Dosage information is not available
Risk reduction for recurrent preterm birth
- Inject 1 milliliter (250 mg) by intramuscular route once weekly beginbetween weeks 16 and 20; continue to week 37 of gestation or delivery
- None
Contraindicated
- None
Severe
Moderate
- None
- Carcinoma of breast
- Deep venous thrombosis
- Disease of liver
- Jaundice
- Neoplasm of liver
- Porphyria
- Predisposition to thrombosis
- Thromboembolic disorder
Contraindicated
- Hypertension
- Mild pre-eclampsia
- Severe pre-eclampsia
Severe
Moderate
- Asthma
- Chronic heart failure
- Depression
- Diabetes mellitus
- Edema
- Kidney disease with reduction in GFR
- Migraine
- Seizure disorder
HYDROXYPROGESTERONE CAPROATE (HYDROXYPROGESTERONE CAPROATE)
- Risk reduction for recurrent preterm birth
- Abnormal uterine bleeding due to hormonal imbalance
- Adenocarcinoma of corpus uteri
- Amenorrhea
- Endogenous estrogen production test
- None
- Edema
- Injection site sequelae
More Frequent
Severe
Less Severe
- Hypersensitivity drug reaction
- Hypertension
- Diarrhea
- Dizziness
- Localized edema
- Nausea
- Pruritus of skin
- Subcutaneous nodules
- Urticaria
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Angioedema
- Depression
- Dyspnea
- Jaundice
- Pulmonary thromboembolism
- Thrombotic disorder
Less Severe
- Body fluid retention
- Chest discomfort
- Fatigue
- Fever
- Flushing
- Headache disorder
- Short cervical length in pregnancy
- Skin rash
- Urinary tract infection
- Vomiting
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Hydroxyprogesterone (Inj)
Safety and efficacy not established age < 16 years.
- 1 Day – 16 Years
- Safety and efficacy not established age < 16 years.
Hydroxyprogesterone Caproate
- Severity Level:
2
- Additional Notes: Indicated in some women to reduce pre-term birth risks.
Contraindicated
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Precaution Exists
Hydroxyprogesterone
Insufficient data available
General | Excretion Potential | Effect on Infant | Notes |
Evaluate use carefully | Excreted | Not known; no or inclusive data | Insufficient data available |
No Known Risk
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
Abnormal uterine bleeding due to hormonal imbalance | |
N92.4 | Excessive bleeding in the premenopausal period |
N92.5 | Other specified irregular menstruation |
N92.6 | Irregular menstruation, unspecified |
N93.8 | Other specified abnormal uterine and vaginal bleeding |
N93.9 | Abnormal uterine and vaginal bleeding, unspecified |
N95.0 | Postmenopausal bleeding |
Adenocarcinoma of corpus uteri | |
C54.1 | Malignant neoplasm of endometrium |
C54.8 | Malignant neoplasm of overlapping sites of corpus uteri |
Amenorrhea | |
N91.0 | Primary amenorrhea |
N91.1 | Secondary amenorrhea |
N91.2 | Amenorrhea, unspecified |
0-9 | A-Z |
---|---|
C54.1 | Malignant neoplasm of endometrium |
C54.8 | Malignant neoplasm of overlapping sites of corpus uteri |
N91.0 | Primary amenorrhea |
N91.1 | Secondary amenorrhea |
N91.2 | Amenorrhea, unspecified |
N92.4 | Excessive bleeding in the premenopausal period |
N92.5 | Other specified irregular menstruation |
N92.6 | Irregular menstruation, unspecified |
N93.8 | Other specified abnormal uterine and vaginal bleeding |
N93.9 | Abnormal uterine and vaginal bleeding, unspecified |
N95.0 | Postmenopausal bleeding |
Formulary Reference Tool